RELMADA THERAPEUTICS, INC. Proceeds from Issuance of Warrants
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Issuance of Warrants of $1.26 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2023-03-23
- RELMADA THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2019-09-30 was $2.02M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2019-06-30 was $10.86M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2019-03-31 was $1.73M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2017-12-31 was $549.80K.
- RELMADA THERAPEUTICS, INC. proceeds from issuance of warrants for fiscal 2022 was $1.26M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance of warrants for fiscal 2015 was $25.45K.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.26M 10-K · filed 2023-03-23 | |||
| 2020-06-30 | $19.86M 10-Q · filed 2020-08-12 | |||
| 2019-09-30 | $2.02M 10-Q · filed 2019-11-13 | $12.88M derived: sum of 2 quarters · filed 2020-08-12 | $14.60M derived: sum of 3 quarters · filed 2020-08-12 | |
| 2019-06-30 | $10.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $12.58M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $1.73M 10-Q · filed 2020-05-15 | |||
| 2017-12-31 | $549.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12 | $1.47M 10-Q · filed 2018-02-12 | ||
| 2017-09-30 | $917.20K 10-Q · filed 2017-11-14 | |||
| 2015-06-30 | -$13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | -$13.40M derived: sum of 2 quarters · filed 2016-09-09 | -$4.27M derived: sum of 3 quarters · filed 2016-09-09 | $25.45K 10-K · filed 2016-09-09 |
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | $9.13M derived: sum of 2 quarters · filed 2015-05-15 | $13.42M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $9.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $13.42M 10-Q · filed 2015-02-13 | ||
| 2014-09-30 | $4.30M 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |